Intrinsic Imaging Awarded Phase I/II Trial of Novel Cancer Therapy
News Jul 15, 2013
During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
Intrinsic Imaging, an FDA audited, ISO 9001 and ISO 13485 certified imaging core lab specializing in providing imaging core lab services for clinical trials, announced that it was awarded a multicenter Phase I/II clinical trial designed to evaluate a new therapy to treat patients with metastatic colorectal cancer (mCRC).
This clinical research study utilizes a novel investigational biologic treatment for patients with unresectable liver metastases in patients with colorectal cancer. During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
“Advances in medical research have created several new options focused on the treatment of metastatic colorectal cancer. There remains, however, significant challenges in achieving long-term survival in those patients with metastatic disease. The continued development and evaluation of novel therapies is necessary to benefit patients suffering from this disease,“ said Dr. Amit Mehta, Chief Medical Officer, Intrinsic Imaging.
Intrinsic Imaging’s team of more than sixty board-certified diagnostic radiologists has sub-specialization in all therapeutic areas including, but not limited to, Oncology, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, and Medical Device. The Intrinsic Oncology team consists of 12 fellowship trained board-certified radiologists, and 8 board-certified interventional radiologists who have in-depth experience in, colorectal, pancreatic, breast, lung, ovarian and prostate cancer, among others.
“Colorectal cancer (CRC) continues to be a global public health problem with over 1 million new cases diagnosed each year. Intrinsic Imaging is dedicated to applying our therapeutic and regulatory expertise throughout this clinical trial towards assisting in the development of a new effective therapy to treat patients with metastatic colorectal cancer,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019